This case illustrates the emergence of an NCOA4–RET fusion as an acquired resistance mechanism in a patient with EGFR exon 19 deletion-positive NSCLC following first-line treatment with osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.